Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$20.66 -0.2%	$19.09	$14.40 ▼ $47.00	$1.37B	1.59	883,869 shs	598,699 shs
DVAX Dynavax Technologies	$11.33 -1.3%	$12.63	$9.74 ▼ $14.63	$1.39B	1.26	2.20 million shs	1.75 million shs
MNKD MannKind	$5.00 +1.0%	$4.94	$4.17 ▼ $7.63	$1.52B	1.22	2.39 million shs	1.64 million shs
VSTM Verastem	$7.43	$6.23	$2.10 ▼ $13.52	$382.57M	0.57	1.03 million shs	575,831 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-0.58%	+5.77%	+22.91%	-15.43%	-47.37%
DVAX Dynavax Technologies	-2.30%	+5.32%	-9.68%	-12.03%	-1.71%
MNKD MannKind	-1.79%	+6.00%	0.00%	-14.51%	+14.06%
VSTM Verastem	-0.80%	-0.93%	+27.66%	+22.20%	-25.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	1.985 of 5 stars	4.5	0.0	0.0	3.5	0.0	0.0
DVAX Dynavax Technologies	4.3668 of 5 stars	3.2	2.0	4.7	3.3	1.7	1.9
MNKD MannKind	3.1242 of 5 stars	3.6	2.0	0.0	3.7	0.8	1.9
VSTM Verastem	3.2086 of 5 stars	4.5	1.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$55.30	167.67% Upside
DVAX Dynavax Technologies	2.33	Hold	$20.50	80.94% Upside
MNKD MannKind	3.22	Buy	$9.56	91.25% Upside
VSTM Verastem	3.00	Buy	$13.89	86.93% Upside

Current Analyst Ratings Breakdown

Latest VSTM, MNKD, CLDX, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/28/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
4/17/2025	DVAX Dynavax Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$12.00 ➝ $10.00
4/10/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$12.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
3/24/2025	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
3/24/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/21/2025	VSTM Verastem	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
3/20/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$46.00
3/3/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$42.00 ➝ $36.00

(Data available from 5/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	195.37	N/A	N/A	$9.08 per share	2.28
DVAX Dynavax Technologies	$277.25M	5.00	N/A	N/A	$4.81 per share	2.36
MNKD MannKind	$285.50M	5.32	N/A	N/A	($0.91) per share	-5.49
VSTM Verastem	$10M	38.26	N/A	N/A	$2.27 per share	3.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.45	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	5/5/2025 (Estimated)
DVAX Dynavax Technologies	-$6.39M	$0.18	62.94	23.12	N/A	9.85%	4.22%	2.67%	5/6/2025 (Estimated)
MNKD MannKind	-$11.94M	$0.10	71.43	21.74	N/A	8.07%	-17.74%	8.68%	5/6/2025 (Estimated)
VSTM Verastem	-$87.37M	-$3.50	N/A	N/A	N/A	N/A	-332.73%	-73.97%	5/8/2025 (Estimated)

Latest VSTM, MNKD, CLDX, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MNKD MannKind	$0.03	N/A	N/A	N/A	$75.86 million	N/A
5/8/2025	Q1 2025	VSTM Verastem	-$0.65	N/A	N/A	N/A	$0.10 million	N/A
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	N/A	N/A	N/A	$70.01 million	N/A
5/5/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	N/A	N/A	N/A	$1.08 million	N/A
3/20/2025	Q4 2024	VSTM Verastem	-$0.76	-$1.33	-$0.57	-$1.33	$0.15 million	N/A
2/27/2025	Q4 2024	CLDX Celldex Therapeutics	-$0.73	-$0.71	+$0.02	-$0.71	$1.25 million	$1.18 million
2/26/2025	Q4 2024	MNKD MannKind	$0.03	$0.03	N/A	$0.03	$74.99 million	$76.78 million
2/20/2025	Q4 2024	DVAX Dynavax Technologies	$0.05	$0.05	N/A	$0.05	$72.70 million	$72.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
DVAX Dynavax Technologies	0.33	13.23	12.34
MNKD MannKind	N/A	4.54	4.17
VSTM Verastem	2.77	3.23	3.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
MNKD MannKind	49.55%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	3.80%
DVAX Dynavax Technologies	2.98%
MNKD MannKind	3.00%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
DVAX Dynavax Technologies	350	122.41 million	127.54 million	Optionable
MNKD MannKind	400	303.85 million	267.51 million	Optionable
VSTM Verastem	50	51.49 million	43.53 million	Optionable

VSTM, MNKD, CLDX, and DVAX Headlines

Recent News About These Companies

B. Riley Has Optimistic Outlook of Verastem FY2029 Earnings

May 2 at 9:24 AM | marketbeat.com

Verastem Oncology to Present at Upcoming Investor Conferences

May 2 at 1:53 AM | finance.yahoo.com

B. Riley Issues Negative Forecast for Verastem Earnings

May 2 at 1:49 AM | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLC

April 28, 2025 | marketbeat.com

Marshall Wace LLP Invests $4.10 Million in Verastem, Inc. (NASDAQ:VSTM)

April 27, 2025 | marketbeat.com

Verastem Oncology Announces $75 million Private Placement | VSTM Stock News

April 25, 2025 | gurufocus.com

Verastem Oncology Announces $75 million Private Placement

April 25, 2025 | gurufocus.com

Verastem Oncology Announces $75 million Private Placement

April 25, 2025 | finance.yahoo.com

Verastem Oncology rises on $75M private placement

April 25, 2025 | seekingalpha.com

Verastem announces U.S. IND clearance of VS-7375

April 25, 2025 | markets.businessinsider.com

Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Walleye Capital LLC

April 24, 2025 | marketbeat.com

Verastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer Treatment

April 23, 2025 | marketwatch.com

Verastem Oncology to initiate trial for its targeted cancer therapy

April 23, 2025 | msn.com

Verastem (VSTM) Gains FDA Nod for Novel Cancer Drug VS-7375

April 23, 2025 | gurufocus.com

Verastem (VSTM) Advances VS-7375 for Cancer Treatment with FDA Approval | VSTM Stock News

April 23, 2025 | gurufocus.com

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, ...

April 23, 2025 | gurufocus.com

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

April 23, 2025 | businesswire.com

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

April 22, 2025 | finance.yahoo.com

Verastem (NASDAQ:VSTM) Rating Lowered to Sell at StockNews.com

April 20, 2025 | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Position Trimmed by Kennedy Capital Management LLC

April 18, 2025 | marketbeat.com

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

April 16, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, MNKD, CLDX, and DVAX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$20.66 -0.05 (-0.24%)

Closing price 04:00 PM Eastern

Extended Trading

$20.66 0.00 (-0.02%)

As of 04:05 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$11.33 -0.15 (-1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$11.26 -0.07 (-0.66%)

As of 05:39 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

MannKind NASDAQ:MNKD

$5.00 +0.05 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$4.97 -0.03 (-0.50%)

As of 07:57 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Verastem NASDAQ:VSTM

$7.43 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.30 -0.13 (-1.68%)

As of 06:26 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time